Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

218
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
218
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

320
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
320
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

178
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
178
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

243
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
243

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026
Same author

Long-term follow-up of autoimmune polyendocrine syndrome type 1 in Norway.

The Journal of clinical endocrinology and metabolism·2026
Same author

Immune Checkpoint Inhibitor Endocrinopathies-Insights From 3 Unusual Cases.

JCEM case reports·2025
Same author

Immune cell subsets in autoimmune polyendocrine syndrome type I.

Scientific reports·2025
Same author

Pasireotide as first line medical therapy for selected patients with acromegaly.

Pituitary·2025
Same author

Awakening not associated with an increased rate of cortisol secretion.

Proceedings. Biological sciences·2025
Same journal

Children's neurodevelopment at school age after hysterosalpingography with iodinated contrast: a cohort study.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Bone phenotype of patients with genetic forms of lipodystrophy: a systematic review of literature.

The Journal of clinical endocrinology and metabolism·2026
Same journal

The Extra X Chromosome and Autoimmune Susceptibility in Klinefelter Syndrome.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Pathophysiology-Based Classification of Male Infertility: Evidence from an 800-patient Prospective Cohort.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Parathyroid Carcinoma: From Molecular Pathogenesis to Multidisciplinary Management.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Genetic and Clinical Factors Associated With Metformin Plasma Concentrations Following an Acute Metformin Challenge.

The Journal of clinical endocrinology and metabolism·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2025

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.3K

Extended-release Hydrocortisone Formulations-Is There a Clinically Meaningful Benefit?

Sandra D Steintorsdottir1,2,3, Marianne Øksnes1,2, Anders P Jørgensen3,4

  • 1Department of Clinical Medicine, University of Bergen, Bergen N-5020, Norway.

The Journal of Clinical Endocrinology and Metabolism
|December 10, 2024
PubMed
Summary
This summary is machine-generated.

Extended-release hydrocortisone (ER-HC) may improve quality of life for adrenal insufficiency patients. This review examines if ER-HC offers significant benefits over conventional therapy.

Keywords:
Addison's diseaseadrenal insufficiencyextended-release hydrocortisone (ER-HC)glucocorticoid replacement therapyimmediate-release hydrocortisone (IR-HC)

More Related Videos

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

9.6K
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.1K

Related Experiment Videos

Last Updated: Jun 5, 2025

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.3K
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

9.6K
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.1K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Clinical Medicine

Background:

  • Adrenal insufficiency patients experience reduced quality of life despite corticosteroid therapy.
  • Conventional hydrocortisone has a short half-life, necessitating frequent dosing.
  • Extended-release hydrocortisone (ER-HC) formulations allow less frequent dosing.

Purpose of the Study:

  • To review studies comparing ER-HC with conventional hydrocortisone for adrenal insufficiency.
  • To assess the safety and clinical benefits of ER-HC formulations.
  • To investigate the reasons behind ER-HC's reported effects.

Main Methods:

  • Systematic review of comparative studies on hydrocortisone formulations.
  • Analysis of pharmacokinetic and pharmacodynamic data.
  • Evaluation of clinical outcomes including quality of life, metabolic parameters, and safety.

Main Results:

  • Studies suggest ER-HC may lead to reduced body weight, blood pressure, and glucose levels.
  • Improved quality of life is frequently reported with ER-HC use.
  • The precise mechanisms (cortisol exposure vs. pharmacokinetics) require further elucidation.

Conclusions:

  • ER-HC formulations offer a potentially improved treatment option for adrenal insufficiency.
  • Further research is needed to confirm long-term safety and clinical significance.
  • Understanding the pharmacokinetic differences is key to optimizing ER-HC therapy.